MENOMUNE

Description

Menomune vaccine is a lyophilized Meningococcal polysaccharide vaccine, groups A,C,Y and W-135 combined, indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y and W-135. Menomune vaccine is approved for use in 2 years old and above. Menomune vaccine does not prevent N meningitidis serogroup B disease.

Immunization guideline:

Primary Vaccination: A single primary dose of 0.5 ml should be injected subcutaneously at 2 years of age.

For latest IAP updates see revised immunization schedule.

Additional information

manufacturer

Sanofi Pasteur

country-of-manufacture

USA

pharmaceutical-form

Liquid, Ready to Use

Vaccine Type

MeningococcalACYW-135 (conjugate vaccine)

package-size

1 Dose

route-of-administration

Intramuscular

preservative

Thiomersal

Contraindications

Do not administer to anyone with the history of severe allergic reaction to Menomune vaccine A, C, Y and W-135 or any component of vaccine.